New Drug Reviews
Telaprevir: A Hepatitis C NS3/4A Protease Inhibitor
Telaprevir is a hepatitis C NS3/4A protease inhibitor approved by the US Food and Drug Administration as part of combination therapy for the management of chronic hepatitis C virus (HCV) genotype 1 infection.Fidaxomicin: The Newest Addition to the Armamentarium Against Clostridium difficile Infections
Fidaxomicin, a macrolide antibiotic, was the first medication for the management of Clostridium difficile infections (CDI) to be approved by the US Food and Drug Administration in more than 20 years.
